Instil Bio Q3 net loss per share narrows
Instil Bio's Q3 net loss per share improved to $2.01 from $3.54 year-over-year. The company's cash and investments decreased to $83.4 million from $115.1 million. Research and development expenses rose to $9.1 million from $0.6 million, indicating investment in clinical trials. Analysts rate the stock as a "buy," with a median 12-month price target of $88.00, significantly above the current price of $14.99.
)
Overview
- Instil Bio Q3 net loss per share improves to $2.01 from $3.54 yr/yr
- Company’s cash and investments fall to $83.4 mln from $115.1 mln at end of 2024
- Research and development expenses rise to $9.1 mln from $0.6 mln yr/yr
Outlook
- Instil expects cash resources to fund operations beyond 2026
Result Drivers
- R&D EXPENSES - Research and development expenses increased to $9.1 mln from $0.6 mln yr/yr, reflecting investment in clinical trials
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Basic -$2.01
EPS
Analyst Coverage
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 3 “strong buy” or “buy”, 1 “hold” and no “sell” or “strong sell”
- The average consensus recommendation for the biotechnology & medical research peer group is “buy”
- Wall Street’s median 12-month price target for Instil Bio Inc is $88.00, about 83% above its November 12 closing price of $14.99
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
